<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03885453</url>
  </required_header>
  <id_info>
    <org_study_id>08/2018</org_study_id>
    <nct_id>NCT03885453</nct_id>
  </id_info>
  <brief_title>Construction of a Questionnaire on Panic Disorder and Agoraphobia</brief_title>
  <official_title>Construction of a Questionnaire on Panic Disorder and Agoraphobia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ulrike Willutzki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Witten/Herdecke</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For the first time panic disorder and agoraphobia are included as separate disorders in the
      DSM-5. Thus, agoraphobia no longer represents a subcategory of panic disorder. To diagnose
      both of the disorders, questionnaires are the method of choice. However, there are no
      measuring instruments available free of charge in German-speaking countries. In order to
      improve this situation, the Witten Panic Disorder Questionnaire (WPF) and the Witten
      Agoraphobia Questionnaire (WAF) are constructed in accordance with the DSM-5 criteria. Both
      measuring instruments are included as a part of a ten instrument battery. WAF and WPF will be
      delivered to a patient sample of patients with panic disorder and/or agoraphobia as well as
      depressed patients (discriminant validity). Factor analyzes and item analyses will be
      conducted.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2019</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Wittener Panik Fragebogen (WPF)</measure>
    <time_frame>5 min</time_frame>
    <description>Self developed panic disorder questionnaire. Measures panic symptoms on one scale. Items are averaged. Range: 1-5. Higher values represent a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WAF</measure>
    <time_frame>10 min</time_frame>
    <description>Self developed agoraphobia questionnaire. Measures agoraphobia symptoms on two scales (Fear and Avoidance). Items are averaged to calculate the subscales. Range: 1-5 (Fear); 1-3 (Avoidance). Higher values represent a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Agoraphobic Cognition Questionnaire (ACQ)</measure>
    <time_frame>5 min</time_frame>
    <description>Chambless et al. (1985); Ehlers et al. (1993). The questionnaire measures anxious thoughts on two scales: Loss of Control and Physical Concerns. Items are averaged to calculate the subscales. Range: 1-5. A total score is calculated by averaging all items. Higher values represent a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Sensations Questionnaire (BSQ)</measure>
    <time_frame>5 min</time_frame>
    <description>Chambless et al. (1985); Ehlers et al. (1993). The questionnaire measures body sensations that may occur in a feared situation. Items are averaged to calculate a total score. Range: 1-5. Higher values represent a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mobility Inventory (MI)</measure>
    <time_frame>10 min</time_frame>
    <description>Chambless et al. (1985); Ehlers et al. (1993). The questionnaire measures avoidance of agoraphobic situations on two scales (Avoidance Alone and Avoidance Accompanied). Items are averaged to calculate the scales. Range: 1-5. Higher values represent a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Agoraphobic Self-Statements Questionnaire (ASQ)</measure>
    <time_frame>5 min</time_frame>
    <description>Hout et al. (2001). Measures agoraphobic statements on two scales (positive self-statements and negative self-statements). Items are averaged. Range: 0-4. Higher values represent a better outcome on the positive scale and a worse outcome on the negative scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Agoraphobic Cognitions Scale - extended version (ACS+)</measure>
    <time_frame>5 min</time_frame>
    <description>Hoffart et al. (1992). Measures fearful cognitions on three scales (fear of bodily incapacitation, fear of losing control, and fear of acting embarrassingly). Items are averaged to calculate the scales. Range: 0-4. Higher values represent a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Health Questionnaire - D (PHQ-D) - Subscale Panic Syndrome</measure>
    <time_frame>5 min</time_frame>
    <description>Spitzer, Kroenke &amp; Williams (1999); LÃ¶we et al. (2002). The questionnaire measures symptoms on modular scales. The panic syndrome subscale is calculated by summing up all 11 items. The scale ranges from 0 to 1. The sum score ranges from 0 to 11. Higher values represent a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Symptom Inventory (BSI)</measure>
    <time_frame>10 min</time_frame>
    <description>Derogatis &amp; Melisaratos (1983); Franke (2000). Measures psychopathological symptoms on nine scales (Somatization, Obsessive-Compulsive, Interpersonal Sensitivity, Depression, Anxiety, Hostility, Phobic Anxiety, Paranoid Ideation, Psychoticism). Items are averaged to calculate the subscale scores. Range: 0-4. The Global Severity Index (GSI) is calculated by averaging all items. Higher values represent a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory (BDI)</measure>
    <time_frame>10 min</time_frame>
    <description>Beck et al. (1961). Measures depressive symptoms on one scale. Items summed up to calculate the toal score. The scale ranges from 0 to 3. The sum score ranges from 0 to 63. Higher values represent a worse outcome.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Panic Disorder</condition>
  <condition>Panic Disorder With Agoraphobia</condition>
  <condition>Agoraphobia</condition>
  <condition>Agoraphobia With Panic Attacks</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Panic Disorder / Agoraphobia</arm_group_label>
    <description>Patients with Panic Disorder / Agoraphobia as major diagnosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Depression</arm_group_label>
    <description>Patients with Depression as major diagnosis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Panic Disorder / Agoraphobia / Depression
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Panic Disorder / Agoraphobia / Depression diagnosis via diagnostic interview

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Witten/Herdecke University</name>
      <address>
        <city>Witten</city>
        <state>North Rhine-Westphalia</state>
        <zip>58455</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Willutzki, Prof</last_name>
      <phone>+49 (0)2302 / 926-767</phone>
      <email>Ulrike.Willutzki@uni-wh.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>December 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Witten/Herdecke</investigator_affiliation>
    <investigator_full_name>Ulrike Willutzki</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Panic Disorder</mesh_term>
    <mesh_term>Agoraphobia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

